You are currently viewing a new version of our website. To view the old version click .
Hematology Reports
  • Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
  • Case Report
  • Open Access

28 June 2013

An Attempt to Induce Transient Immunosuppression Pre-Erythrocytapheresis in a Girl with Sickle Cell Disease, a History of Severe Delayed Hemolytic Transfusion Reactions and Need for Hip Prosthesis

,
,
,
,
,
,
,
and
1
Pediatric Department, University of Milano-Bicocca, San Gerardo Hospital, Via Pergolesi 33, 20052 Monza, MB, Italy
2
Immunotransfusional Service, University of Milano-Bicocca, San Gerardo Hospital, Via Pergolesi 33, 20052 Monza, MB, Italy
3
Apheresis Unit, University of Milano-Bicocca, San Gerardo Hospital, Via Pergolesi 33, 20052 Monza, MB, Italy
4
Orthopedic Department, University of Milano-Bicocca, San Gerardo Hospital, Via Pergolesi 33, 20052 Monza, MB, Italy

Abstract

We report on a case of delayed hemolytic transfusion reaction (DHTR) occurred 7 days after an erythrocytapheresis or eritroexchange procedure (EEX) treated with rituximab and glucocorticoids in a 15-years old patient with sickle cell disease. EEX was performed despite a previous diagnosis of alloimmunization, in order to reduce hemoglobin S rate before a major surgery for avascular necrosis of the femoral head. A first dose of rituximab was administered before EEX. However, rituximab couldn’t prevent DHTR that occurred with acute hemolysis, hemoglobinuria and hyper-bilirubinemia. A further dose of rituximab and three boli of methylprednisolone were given after the onset of the reaction. It is likely that the combined use of rituximab and steroids managed to gradually improve both patient’s general conditions and hemoglobin levels. Nor early or late side effects were registered in a 33-months follow-up period. This report suggests the potential effectiveness and safety of rituximab in combination with steroids in managing and mitigating the symptoms of delayed post-transfusional hemolytic reactions in alloimmunized patients affected by sickle cell disease with absolute need for erythrocytapheresis.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.